Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Mem. Inst. Oswaldo Cruz ; 104(8): 1083-1090, Dec. 2009. ilus, tab
Article in English | LILACS | ID: lil-538167

ABSTRACT

Gap junction connexin-43 (Cx43) molecules are responsible for electrical impulse conduction in the heart and are affected by transforming growth factor-â (TGF-â). This cytokine increases during Trypanosoma cruzi infection, modulating fibrosis and the parasite cell cycle. We studied Cx43 expression in cardiomyocytes exposed or not to TGF-â T. cruzi, or SB-431542, an inhibitor of TGF-â receptor type I (ALK-5). Cx43 expression was also examined in hearts with dilated cardiopathy from chronic Chagas disease patients, in which TGF-â signalling had been shown previously to be highly activated. We demonstrated that TGF-â treatment induced disorganised gap junctions in non-infected cardiomyocytes, leading to a punctate, diffuse and non-uniform Cx43 staining. A similar pattern was detected in T. cruzi-infected cardiomyocytes concomitant with high TGF-â secretion. Both results were reversed if the cells were incubated with SB-431542. Similar tests were performed using human chronic chagasic patients and we confirmed a down-regulation of Cx43 expression, an altered distribution of plaques in the heart and a significant reduction in the number and length of Cx43 plaques, which correlated negatively with cardiomegaly. We conclude that elevated TGF-â levels during T. cruzi infection promote heart fibrosis and disorganise gap junctions, possibly contributing to abnormal impulse conduction and arrhythmia that characterise severe cardiopathy in Chagas disease.


Subject(s)
Adult , Animals , Female , Humans , Male , Mice , Middle Aged , Benzamides/therapeutic use , Chagas Disease/metabolism , /metabolism , Dioxoles/therapeutic use , Gap Junctions/metabolism , Myocytes, Cardiac/chemistry , Receptors, Transforming Growth Factor beta/antagonists & inhibitors , Transforming Growth Factor beta/therapeutic use , Chagas Disease/drug therapy , Fluorescent Antibody Technique , Gap Junctions/drug effects , Immunohistochemistry , Microscopy, Confocal , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism
2.
Article in English | IMSEAR | ID: sea-139893

ABSTRACT

Objective: The present study histologically and radiologically evaluates the muscle tissue of rats after implantation of bone morphogenic protein (rhBMP-2) in a natural inorganic bone mineral scaffold from a bull calf femur and irradiation with low-power light laser. Materials and Methods: The right and left hind limbs of 16 rats were shaved and an incision was made in the muscle on the face corresponding to the median portion of the tibia, into which rhBMP-2 in a scaffold of inorganic bone was implanted. Two groups of limbs were formed: control (G1) and laser irradiation (G2). G2 received diode laser light applied in the direction of the implant, at a dose of 8 J/cm2 for three minutes. On the 7th, 21st, 40th and 112th days after implantation, hind limbs of 4 animals were radiographed and their implants removed together with the surrounding tissue for study under the microscope. The histological results were graded as 0=absence, 1=slight presence, 2=representative and 3=very representative, with regard to the following events: formation of osteoid structure, acute inflammation, chronic inflammation, fibrin deposition, neovascularization, foreign-body granuloma and fibrosis. Results: There were no statistically significant differences in these events at each evaluation times, between the two groups (P>0.05; Mann-Whitney test). Nevertheless, it could be concluded that the natural inorganic bone matrix with rhBMP-2, from the femur of a bull calf, is a biocompatible combination. Conclusions: Under these conditions, the inductive capacity of rhBMP-2 for cell differentiation was inhibited. There was a slight acceleration in tissue healing in the group that received irradiation with low-power laser light.


Subject(s)
Absorbable Implants , Animals , Biocompatible Materials/therapeutic use , Bone Matrix/drug effects , Bone Matrix/radiation effects , Bone Matrix/transplantation , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/administration & dosage , Bone Morphogenetic Proteins/radiation effects , Bone Morphogenetic Proteins/therapeutic use , Cattle , Cell Differentiation/drug effects , Cell Differentiation/radiation effects , Fibrin/analysis , Fibrosis , Granuloma, Foreign-Body/etiology , Granuloma, Foreign-Body/pathology , Inflammation , Low-Level Light Therapy/methods , Lasers, Semiconductor/therapeutic use , Male , Muscle, Skeletal/pathology , Muscle, Skeletal/diagnostic imaging , Muscle, Skeletal/surgery , Neovascularization, Physiologic/drug effects , Neovascularization, Physiologic/radiation effects , Osteogenesis/drug effects , Osteogenesis/radiation effects , Radiation Dosage , Rats , Rats, Wistar , Recombinant Proteins/administration & dosage , Recombinant Proteins/radiation effects , Recombinant Proteins/therapeutic use , Time Factors , Tissue Scaffolds , Transforming Growth Factor beta/administration & dosage , Transforming Growth Factor beta/radiation effects , Transforming Growth Factor beta/therapeutic use , Wound Healing/drug effects , Wound Healing/radiation effects
3.
Rev. clín. pesq. odontol. (Impr.) ; 4(3): 129-136, set.-dez. 2008. ilus
Article in English | LILACS, BBO | ID: lil-617350

ABSTRACT

OBJECTIVES: Recent studies of pulpotomy and direct pulp capping using bone morphogeneticprotein (BMP) in the teeth of animals have indicated a role for BMP in the induction and biologicalproduction of dentin. The aim of this study was to observe painful reactions and signs of clinicaland radiographic pathological alterations in human deciduous teeth, as well as to histologicallyexamine pulp tissue after the use of recombinant human BMP-2 in a collagen scaffold. MATERIALAND METHOD: Five deciduous teeth for which pulpotomy had been indicated were studied.rhBMP-2 was placed in the pulp chamber of the teeth, and they were then filled using compositeresin. In two teeth that exfoliated, histological examinations were performed. RESULTS: Aftertwelve months, we observed 100% clinical and radiographic success, with no detectableabnormalities. On the histological sections, areas of inflammation, pulp necrosis and internalreabsorption, as well as the formation of tissue resembling osteodentin in the radicular portion,were observed. CONCLUSIONS: It could be concluded that the absence of symptomatologyand clinical and radiographic alterations suggests that rhBMP-2 is a material with inductive propertiesthat should be further investigated for use as an alternative to pulpotomy treatment.


OBJETIVOS: A proposta deste estudo foi observar as reações álgicas, sinais de alteraçõespatológicas (clínica e radiográfica) e examinar histologicamente o tecido pulpar de molaresdecíduos humanos, após o uso de BMP-2 recombinante humano em arcabouço de colágeno.MATERIAL E MÉTODO: Foram utilizados cinco molares decíduos de crianças entre oito edez anos, com indicação de pulpotomia. Após execução da técnica, na câmara foi acomodadaa rhBMP-2 em colágeno e o dente restaurado com resina composta. Estes pacientes foramacompanhados durante doze meses, dois dentes que esfoliaram foram realizados exameshistológicos (H.E.). RESULTADOS: Após este período observou-se sucesso clínico eradiográfico de 100%, pois nenhuma anormalidade foi detectada. Foram observadas noscortes histológicos, áreas de inflamação, necrose pulpar e reabsorção interna, também formaçãode tecido semelhante a osteodentina. CONCLUSÕES: Pode-se concluir que as ausências desintomas e de alterações clínicas e radiográficas sugerem que as rhBMP-2 em arcabouço decolágeno são materiais com propriedades indutivas que devem ser melhor pesquisadas paraque se tornem alternativa para as pulpotomias.


Subject(s)
Humans , Child , Bone Morphogenetic Proteins/therapeutic use , Dental Pulp/pathology , Pulpotomy/methods , Recombinant Proteins/therapeutic use , Tooth, Deciduous/pathology , Transforming Growth Factor beta/therapeutic use , Biocompatible Materials , Materials Testing , Treatment Outcome
4.
Rev. Asoc. Argent. Ortop. Traumatol ; 72(4): 373-381, dic. 2007. ilus
Article in Spanish | LILACS | ID: lil-482600

ABSTRACT

Introducción: Debido a los cambios recientes en torno al tratamiento de las fracturas, en los últimos años se ha priorizado una combinación de métodos no sólo mecánicos sino también biológicos. En este estudio se evalúan los resultados de un tratamiento combinado mediante osteosíntesis y aplicación de injerto enriquecido con agregado plaquetario, con resultados alentadores. Materiales y métodos: Nuestra serie comprendió 29 pacientes tratados entre 1999 y 2006, laboralmente activos, con una edad promedio de 42 años (rango, 26 a 62 años). En todos los casos se efectuó osteosíntesis con el agregado plaquetario rico en factores de crecimiento plaquetario. Los resultados se analizaron en función de la formación de callo fracturario a los 6 meses. La obtención de injerto esponjoso fue dificultosa en los pacientes reintervenidos. Resultados: La obtención y preparación del agregado plaquetario no presentó inconvenientes. La consolidación clínica y radiológica se alcanzó en los 29 casos al término de 4 meses (2-6 meses); en 2 casos fue necesario repetir el procedimiento de aporte sin recambio del implante a los 2 meses de la primera intervención. Conclusiones: El injerto autólogo enriquecido con plasma rico en factores de crecimiento pudo haber contribuido de manera favorable a la consolidación de estos casos complejos, con gran ausencia biológica, en los que habían fracasado otros métodos


Subject(s)
Humans , Adult , Middle Aged , Bone Regeneration , Fracture Healing , Fractures, Bone/therapy , Fractures, Ununited/therapy , Growth Substances/therapeutic use , Transplantation, Autologous , Combined Modality Therapy , Fibroblast Growth Factor 2 , Transforming Growth Factor beta/therapeutic use , Platelet-Derived Growth Factor/therapeutic use , Treatment Outcome
5.
Rev. Asoc. Argent. Traumatol. Deporte ; 14(2): 28-30, 2007. ilus
Article in Spanish | LILACS | ID: lil-490467

ABSTRACT

La patología del cartílago articular es frecuente en la traumatología, por eso es de nuestro interés dilucidar e investigar la ultraestructura y estructura de la lesión, la reparación de este tejido, con el fin de conseguir avances clínicos en la evolución de estas lesiones frecuentes. Los traumatismos, las lesiones por sobreuso y sobrecarga producen alteraciones en el cartílago, cuyos mecanismos de producción y reparación no han sido aún bien estudiados. El conocimiento de los mismos podría ser de gran aporte para evaluar si la aplicación de factores de crecimiento y el estudio de la modulación del oxido nítrico pueden tener una proyección terapéutica. Existen pocos trabajos que reportan el valor del óxido nítrico y los factores de crecimiento en el desarrollo y la reparación de estas lesiones, y debido al costo económico que provoca la abundancia de estas lesiones a los sistemas de salud, y las secuelas que provocan con el desarrollo tórpido y los tratamientos equívocos que se realizan hoy en día, es importante el estudio y mejora de su evolución para el bienestar del paciente y para disminuir el tiempo de regreso a la actividad laboral que el paciente ejercía.


Subject(s)
Animals , Rats , Cartilage, Articular/pathology , Transforming Growth Factor beta/therapeutic use , Nitric Oxide/therapeutic use , Bone Morphogenetic Proteins/therapeutic use , Receptor, IGF Type 1/therapeutic use , Growth Substances/therapeutic use , Acute Disease , Wounds and Injuries/therapy , Cumulative Trauma Disorders/therapy
6.
Salud pública Méx ; 46(4): 341-350, jul.-ago. 2004. ilus
Article in Spanish | LILACS | ID: lil-383258

ABSTRACT

El factor de crecimiento transformante beta (TGF-beta) es una familia de proteínas que incluye al TGF-beta, activinas y a la proteína morfogénica de hueso (BMP, por sus siglas en inglés), citocinas que son secretadas y se relacionan estructuralmente en diferentes especies de metazoarios. Los miembros de la familia del TGF-beta regulan diferentes funciones celulares como proliferación, apoptosis, diferenciación, migración, y tienen un papel clave en el desarrollo del organismo. El TGF-beta está implicado en varias patologías humanas, incluyendo desórdenes autoinmunes y vasculares, así como enfermedades fibróticas y cáncer. La activación del receptor del TGF-beta propicia su fosforilación en residuos de serina/treonina y dispara la fosforilación de proteínas efectoras intracelulares (smad), que una vez activas se translocan al núcleo para inducir la transcripción de genes blanco, y así regular procesos y funciones celulares. Se están desarrollando novedosas estrategias terapéuticas encaminadas a corregir las alteraciones presentes en patologías que involucran al TGF-beta como actor principal.


Subject(s)
Animals , Humans , Transforming Growth Factor beta/therapeutic use , Clinical Trials as Topic , Phosphorylation
7.
Rev. bras. odontol ; 55(5): 286-92, set.-out. 1998. tab
Article in Portuguese | LILACS, BBO | ID: lil-230292

ABSTRACT

A busca da manutençäo da vitalidade e integridade pulpar tem sido um fato corriqueiro na odontologia moderna. Tentativas de proteçäo pulpar direta ocorrem desde o século XVIII. Vários materiais têm sido propostos com esta finalidade, apresentando qualidades favoráveis e desfavoráveis que devem ser consideradas. Em 1920, Hermann introduziu o hidróxido de cálcio, que se tornou um marco histológico para a preservaçäo pulpar. A partir desta época, várias outras substâncias e associaçöes foram propostas, desde o cimento de óxido de zinco e eugenol até materiais mais recentes, como o agregado de trióxido mineral


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Dental Pulp Capping , Dentin-Bonding Agents , Calcium Hydroxide/therapeutic use , Pulpotomy , Transforming Growth Factor beta/therapeutic use , Eugenol/therapeutic use , Zinc Oxide/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL